03. September 2026
14:00 - 19:00 Uhr
Keynote speeches, short presentations and panel discussions in which trends and innovation across various sectors are discussed.
For anyone who wants to break down silos and help shape the future of Switzerland’s life sciences sector through genuine cross-sector innovation.
Switzerland offers key conditions for innovative ideas and solutions, yet growth and value creation are increasingly taking place abroad. The event will discuss how the country can maintain its excellence and avoid a shift to more attractive locations. tfz Innovation Inside Pharma is the innovation hub for a cross-sector networked pharmaceutical hub in Switzerland. We bring together over 100 top decision-makers from industry, cutting-edge research and public authorities to highlight technological trends and jointly shape the healthcare of tomorrow – in a practical, networked and solution-oriented way.
| 14:00 Uhr | Meet & Greet, Coffee |
| 14:30 Uhr | Start Programme featuring exciting keynote speeches and power slots |
| 15:45 Uhr | Networking |
| 16:00 Uhr | Programme continues with power slots and interactive panel discussion |
| 17:15 Uhr | Networking & Aperitif |
Geopolitical shifts, regulatory pressure and the global race for innovation: in his opening keynote address, Interpharma CEO René Buholzer addresses the most pressing issues concerning the future of patient care in Switzerland and outlines how Switzerland can maintain its leading position in a volatile world.
From a Basel Lab to a Big Pharma Exit Bacteria as a Cancer Therapy—a radical idea, successfully implemented. This keynote presentation shows how T3 made its way into Big Pharma’s pipelines and what conditions Switzerland needs to successfully scale up innovation.
Process Power Slot: Why a U.S. Pioneer Is Betting on Zug AI-powered antibody development made in Zug: Absci explains firsthand why an international biotech company chose Switzerland as the location for its expansion—and what makes it special.
Innovation Power Slot: Clarifying Toxicity in Clinical Trials—Causality Rather Than Conjecture When a drug causes liver damage in clinical trials—was it the drug, or something else? TransHeps demonstrates how a patient-specific test provides objective answers in ongoing trials and prevents costly trial discontinuations
CEO & Delegate of the Board, Interpharma
Member of the National Council, member of the Committee on Social Security and Health and the Committee on Economic Affairs and Taxation
CEO & Co-Founder, T3 Pharma
The Zug Technology Forum would like to extend its sincere thanks to the ‘tfz Enabler’, Zuger Kantonalbank, and the other sponsors of tfz Innovation Inside Pharma 2026.